NASDAQ:AVXL Anavex Life Sciences (AVXL) Stock Price, News & Analysis $2.60 -0.02 (-0.76%) Closing price 09/14/2026 04:00 PM EasternExtended Trading$2.58 -0.02 (-0.62%) As of 09/14/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Anavex Life Sciences Stock (NASDAQ:AVXL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Anavex Life Sciences alerts:Sign Up Key Stats Today's Range$2.55▼$2.6450-Day Range$2.34▼$3.5652-Week Range$2.26▼$10.38Volume657,928 shsAverage Volume672,577 shsMarket Capitalization$241.02 millionP/E RatioN/ADividend YieldN/APrice Target$21.33Consensus RatingHold Company Overview Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and neurodevelopmental disorders. The company’s research centers on small-molecule treatments intended to address disease mechanisms associated with conditions affecting the central nervous system. Anavex’s lead investigational product is blarcamesine, also known as ANAVEX2-73, an orally administered compound being studied in disorders including Alzheimer’s disease, Parkinson’s disease dementia and Rett syndrome. The company has also evaluated other pipeline candidates, including ANAVEX3-71, for potential use in neurodegenerative diseases. Founded in 2004, Anavex conducts clinical development activities through research and trials involving participants in multiple geographic regions. The company is headquartered in New York and is led by Christopher U. Missling, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Anavex Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreAVXL MarketRank™: Anavex Life Sciences scored higher than 33% of companies evaluated by MarketBeat, and ranked 751st out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingAnavex Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAnavex Life Sciences has a consensus price target of $21.33, representing about 720.5% upside from its current price of $2.60.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Anavex Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anavex Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.92% of the float of Anavex Life Sciences has been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 16.66, which indicates bearish sentiment.Change versus previous monthShort interest in Anavex Life Sciences has recently decreased by 1.48%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.29 News SentimentAnavex Life Sciences has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Anavex Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for AVXL on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows4 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.55% of the stock of Anavex Life Sciences is held by institutions.Read more about Anavex Life Sciences' insider trading history. Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVXL Stock News HeadlinesPVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance3 hours ago | finance.yahoo.comPVG Asset Management Believes ISS Acknowledges Anavex's Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price UnderperformanceSeptember 14 at 7:30 PM | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex’s Highly Qualified Director NomineesSeptember 14 at 8:56 AM | markets.businessinsider.comLeading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote “FOR” All Six of Anavex's Highly Qualified Director NomineesSeptember 14 at 8:30 AM | globenewswire.comBrokerages Set Anavex Life Sciences Corp. (NASDAQ:AVXL) Target Price at $21.33September 11, 2026 | americanbankingnews.comPVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy CampaignSeptember 10, 2026 | globenewswire.comPVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)September 9, 2026 | globenewswire.comSee More Headlines AVXL Stock Analysis - Frequently Asked Questions How have AVXL shares performed this year? Anavex Life Sciences' stock was trading at $3.56 at the start of the year. Since then, AVXL shares have decreased by 27.0% and is now trading at $2.60. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its earnings results on Tuesday, August, 25th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.16. Who are Anavex Life Sciences' major shareholders? Top institutional investors of Anavex Life Sciences include Bank of New York Mellon Corp (0.31%), Apella Capital LLC (0.25%), Hikari Power Ltd (0.09%) and 180 Wealth Advisors LLC (0.08%). Insiders that own company stock include Christopher U Missling, Steffen Thomas and Peter DO Donhauser. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anavex Life Sciences investors own include Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Innovative Industrial Properties (IIPR), Voya Infrastructure, Industrials and Materials Fund (IDE), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/25/2026Today9/14/2026Investor update9/16/2026Fiscal Year End9/30/2026Next Earnings (Estimated)11/24/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 AVXL's financial health is in the Red zone, according to TradeSmith. AVXL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AVXL CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees34Year Founded2006Price Target and Rating Average Price Target for Anavex Life Sciences$21.33 High Price Target$24.00 Low Price Target$20.00 Potential Upside/Downside+720.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-11.43% Return on Assets-10.72% Debt Debt-to-Equity RatioN/A Current Ratio15.62 Quick Ratio15.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book2.36Miscellaneous Outstanding Shares92,700,000Free Float82,500,000Market Cap$241.02 million OptionableOptionable Beta1.14 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:AVXL) was last updated on 9/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
